



Neurotech achieves new milestone with shipment of improved Mente Autism devices

KEY HIGHLIGHTS

- *First shipments of improved version of its Neurofeedback device, Mente Autism*
- *Devices to be delivered to distribution partners across Australia, Europe and the Middle East*
- *Additional devices to be shipped for research purposes in Italy and Middle East*
- *Reimbursement preparations commenced in Australia*

Perth, Australia & Malta – 10 August 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) is pleased to announce that it has completed the first shipments of the next batch of Mente Autism devices.

Pre-orders had been received from several of Neurotech’s distributors with the devices being delivered to Australia, Europe and the Middle East.

Several distribution partners in these regions have commenced marketing and information campaigns to coincide with the release of the next batch devices. Neurotech is also preparing new marketing assets that can be used by distributors to promote Mente Autism in the local press and with key opinion leaders.

Wolfgang Storf, CEO of Neurotech, said: “We are pleased to commence shipping of the improved Mente Autism device to our distribution partners across Europe, Middle East and Australia. This is an important milestone following the US Clinical Trial and we look forward to fulfilling additional orders from our partners. We are ramping up production with a view to completing another shipment of devices in the coming weeks. I would like to take the opportunity to thank my team for their hard work on this updated version of Mente Autism and to our distribution partners who are keen to help us tap into the huge potential market for the device.”

MULTI-SITE STUDIES

The recently announced US Clinical Trial results provide Neurotech with important scientific evidence supporting the use of Mente Autism for children with autism spectrum disorder. As well as carrying significant weight with new and existing distributors of the device, the trial provides pivotal evidence to accompany the FDA submission for Mente Autism.

In addition to this, Neurotech expects to complete several multi-site studies that will further validate the product in different target markets. These studies are aimed at generating awareness and

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

acceptance of the technology in the regions, in addition to supporting potential reimbursement. To this end, the Company has recently appointed a consultant, Mediclever, to support applications for inclusion of Mente Autism on government reimbursement schemes in Australia.

The costs of these projects will largely be borne by the research institutions and their associated grant funding, with Neurotech donating research units and analytical support towards the studies.

As part of this process Neurotech will ship 20 research devices to academic partners in Italy (10) and the Middle East (10) who have agreed to conduct studies in their respective regions, commencing in September. Additional research agreements are currently being finalised.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420